Skip to main content

Foley & Lardner LLP represented Bioluminescence Ventures in its emergence from stealth with $477M in assets under management across two funds: Bioluminescence Ventures Fund I, L.P., and Bioluminescence Ventures Fund II, L.P. The firm is supported by an investor base that includes U.S. and multinational institutional Limited Partners.

Bioluminescence Ventures was conceptualized to finance breakthrough platforms and support mission-driven leaders to develop first-in-class or best-in-class therapies. BLV invests in companies with highly innovative platforms (biological or technological), developing novel therapeutics addressing large patient populations/major unmet medical needs, supported by strong data packages. The firm prefers to lead rounds – working closely with a company’s leadership team to complete diligence, negotiate equitable terms, secure the syndicate, and close the round with speed and efficiency.

The Foley team was co-led by partners Louis Lehot and Raj Tanden and senior counsel Frank White with support from associate Saige Gallop, as well as intellectual property partner Jeff Greene and associate Arian Jabbary.

Foley’s Fund Formation & Investment Management group understands the business objectives, dynamics and trends of GPs, LPs and the entire private funds industry, and is complimented by integrated attorneys with significant backgrounds in tax, ERISA, regulatory, CFIUS/KYC, SEC investigation/examination, litigation, employment, finance, estate planning, and more.

Author Louis Lehot

More Insights by Louis Lehot